Trials / Completed
CompletedNCT01331746
Proof-of-concept (PoC) Study of APD515
Randomised, Double-blind, Placebo-controlled Phase II Proof-of-concept Study of APD515 Solution for Oromucosal and Oral Administration for Relief of Xerostomia in Patients With Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Acacia Pharma Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to look at the effectiveness of a drug called APD515, designed to be applied to the lining inside the mouth, at relieving dryness of the mouth. Study will compare one week of treatment with APD515 to one week of treatment with matching placebo to see which has better effect on patient's mouth dryness, according to their own score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APD515 | 20 mg oromucosal-oral administration qds for 7 days |
| DRUG | Placebo | qds for 7 days |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-04-08
- Last updated
- 2013-05-16
Locations
11 sites across 2 countries: Denmark, United Kingdom
Source: ClinicalTrials.gov record NCT01331746. Inclusion in this directory is not an endorsement.